[go: up one dir, main page]

CL2012001596A1 - Compuestos derivados de triazolopiridina, pirazolopirimidina, triazolopirimidina o pirazolopiridina, modulador alosterico positivo del receptor mglur5; composicion farmaceutica que los comprende; y su uso en el tratamiento y/o prevencion de la esquizofrenia o de una enfermedad cognitiva. - Google Patents

Compuestos derivados de triazolopiridina, pirazolopirimidina, triazolopirimidina o pirazolopiridina, modulador alosterico positivo del receptor mglur5; composicion farmaceutica que los comprende; y su uso en el tratamiento y/o prevencion de la esquizofrenia o de una enfermedad cognitiva.

Info

Publication number
CL2012001596A1
CL2012001596A1 CL2012001596A CL2012001596A CL2012001596A1 CL 2012001596 A1 CL2012001596 A1 CL 2012001596A1 CL 2012001596 A CL2012001596 A CL 2012001596A CL 2012001596 A CL2012001596 A CL 2012001596A CL 2012001596 A1 CL2012001596 A1 CL 2012001596A1
Authority
CL
Chile
Prior art keywords
schizophrenia
prevention
treatment
pharmaceutical composition
triazolopyridine
Prior art date
Application number
CL2012001596A
Other languages
English (en)
Inventor
Heinz Stadler
Wolfgang Guba
Lothar Lindemann
Luke Green
Goerg Jaeschke
Synese Jolidon
Eric Vieira
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43446449&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012001596(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2012001596A1 publication Critical patent/CL2012001596A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compuestos derivados de etinilo, moduladores positivos del receptor de glutamato (MGLUR5); composición farmacéutica que los comprende; uso del compuesto para el tratamiento o la prevención de la esquizofrenia o enfermedades cognitivas.
CL2012001596A 2009-12-17 2012-06-14 Compuestos derivados de triazolopiridina, pirazolopirimidina, triazolopirimidina o pirazolopiridina, modulador alosterico positivo del receptor mglur5; composicion farmaceutica que los comprende; y su uso en el tratamiento y/o prevencion de la esquizofrenia o de una enfermedad cognitiva. CL2012001596A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09179719 2009-12-17

Publications (1)

Publication Number Publication Date
CL2012001596A1 true CL2012001596A1 (es) 2013-01-04

Family

ID=43446449

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012001596A CL2012001596A1 (es) 2009-12-17 2012-06-14 Compuestos derivados de triazolopiridina, pirazolopirimidina, triazolopirimidina o pirazolopiridina, modulador alosterico positivo del receptor mglur5; composicion farmaceutica que los comprende; y su uso en el tratamiento y/o prevencion de la esquizofrenia o de una enfermedad cognitiva.

Country Status (27)

Country Link
US (2) US8586581B2 (es)
EP (1) EP2513102B1 (es)
JP (1) JP5763094B2 (es)
KR (1) KR101407856B1 (es)
CN (1) CN102686589B (es)
AR (1) AR079467A1 (es)
AU (1) AU2010332987B2 (es)
BR (1) BR112012014770A2 (es)
CA (1) CA2780155A1 (es)
CL (1) CL2012001596A1 (es)
CO (1) CO6531478A2 (es)
CR (1) CR20120269A (es)
EC (1) ECSP12011977A (es)
ES (1) ES2551582T3 (es)
IL (1) IL219371A (es)
MA (1) MA33802B1 (es)
MX (1) MX2012006789A (es)
MY (1) MY162998A (es)
NZ (1) NZ599553A (es)
PE (1) PE20121443A1 (es)
PH (1) PH12012500867A1 (es)
RU (1) RU2553461C2 (es)
SG (1) SG181779A1 (es)
TW (1) TWI448465B (es)
UA (1) UA107002C2 (es)
WO (1) WO2011073172A1 (es)
ZA (1) ZA201204429B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103201259B (zh) 2010-11-05 2015-05-27 日本欧爱特农业科技株式会社 乙炔基苯脒化合物或其盐、其制备方法和用于农业和园艺的杀菌剂
HUE025031T2 (en) 2011-04-26 2016-02-29 Hoffmann La Roche Ethinyl derivatives as positive allosteric modulators of MGLUR5
US20130123254A1 (en) 2011-09-30 2013-05-16 Barbara Biemans Pharmaceutically acceptable mglur5 positive allosteric modulators and their methods of identification
UA110862C2 (uk) * 2011-10-07 2016-02-25 Ф. Хоффманн-Ля Рош Аг Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5
PL2900659T3 (pl) * 2012-09-27 2017-02-28 F.Hoffmann-La Roche Ag Pochodne aryloetynylowe
NZ703537A (en) * 2012-10-18 2018-06-29 Hoffmann La Roche Ethynyl derivatives
MX2015005375A (es) * 2012-11-07 2015-07-21 Hoffmann La Roche Compuestos de triazolo.
CN107849006B (zh) 2015-06-03 2020-11-13 豪夫迈·罗氏有限公司 乙炔基衍生物
HUE045145T2 (hu) 2015-07-15 2019-12-30 Hoffmann La Roche Etinil-származékok metabotróp glutamátreceptor-modulátorokként
JP6936305B2 (ja) 2016-07-18 2021-09-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ エチニル誘導体

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000020001A1 (en) * 1998-10-02 2000-04-13 Novartis Ag Mglur5 antagonists for the treatment of pain and anxiety
AR029803A1 (es) * 2000-02-21 2003-07-16 Smithkline Beecham Plc Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
GB0027987D0 (en) * 2000-11-16 2001-01-03 Smithkline Beecham Plc Compounds
US6910976B2 (en) 2001-06-26 2005-06-28 Stx, Llc Multi-component lacrosse stick head
GB0127430D0 (en) * 2001-11-15 2002-01-09 Smithkline Beecham Corp Compounds
GB0127433D0 (en) * 2001-11-15 2002-01-09 Smithkline Beecham Corp Compounds
TWI292318B (en) * 2003-03-10 2008-01-11 Hoffmann La Roche Imidazol-4-yl-ethynyl-pyridine derivatives
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
GB0413605D0 (en) 2004-06-17 2004-07-21 Addex Pharmaceuticals Sa Novel compounds
WO2006048771A1 (en) 2004-11-04 2006-05-11 Addex Pharmaceuticals Sa Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
CA2610042C (en) * 2005-06-01 2013-04-23 Ucb Pharma, S.A. 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
DE602006009968D1 (de) 2005-11-15 2009-12-03 Array Biopharma Inc N4-phenyl-chinazolin-4-aminderivate und verwandte verbindungen als inhibitoren der erbb-typ-i-rezeptortyrosinkinase zur behandlung hyperproliferativer krankheiten
UY30444A1 (es) 2006-06-30 2008-01-31 Astrazeneca Ab Derivados de pirimidina, procesos para su preparacinn, composiciones farmaccuticos y usos de los mismos.
EP1972628A1 (en) 2007-03-21 2008-09-24 Schwarz Pharma Ag Indolizines and aza-analog derivatives thereof as CNS active compounds
KR20100019470A (ko) * 2007-04-30 2010-02-18 아보트 러보러터리즈 디아실글리세롤 ｏ-아실트랜스퍼라제 타입 １ 효소의 억제제
NZ581817A (en) 2007-06-03 2012-05-25 Univ Vanderbilt Benzamide mglur5 positive allosteric modulators and methods of making and using same
TW201116532A (en) * 2009-08-05 2011-05-16 Merz Pharma Gmbh & Co Kgaa Metabotropic glutamate receptor modulators

Also Published As

Publication number Publication date
JP2013514305A (ja) 2013-04-25
EP2513102B1 (en) 2015-08-19
US8586581B2 (en) 2013-11-19
ZA201204429B (en) 2013-02-27
WO2011073172A1 (en) 2011-06-23
TWI448465B (zh) 2014-08-11
ES2551582T3 (es) 2015-11-20
EP2513102A1 (en) 2012-10-24
RU2553461C2 (ru) 2015-06-20
KR101407856B1 (ko) 2014-06-16
US20110152257A1 (en) 2011-06-23
MA33802B1 (fr) 2012-12-03
US8933094B2 (en) 2015-01-13
KR20120095472A (ko) 2012-08-28
CA2780155A1 (en) 2011-06-23
TW201144314A (en) 2011-12-16
NZ599553A (en) 2014-05-30
SG181779A1 (en) 2012-07-30
HK1171225A1 (en) 2013-03-22
AU2010332987B2 (en) 2015-08-13
MX2012006789A (es) 2012-07-10
AR079467A1 (es) 2012-01-25
BR112012014770A2 (pt) 2016-03-29
IL219371A (en) 2015-02-26
MY162998A (en) 2017-07-31
CO6531478A2 (es) 2012-09-28
AU2010332987A1 (en) 2012-06-07
ECSP12011977A (es) 2012-07-31
PE20121443A1 (es) 2012-10-26
UA107002C2 (uk) 2014-11-10
PH12012500867A1 (en) 2014-10-14
RU2012128551A (ru) 2014-01-27
US20140073638A1 (en) 2014-03-13
IL219371A0 (en) 2012-06-28
CR20120269A (es) 2012-07-04
CN102686589B (zh) 2014-12-10
CN102686589A (zh) 2012-09-19
JP5763094B2 (ja) 2015-08-12

Similar Documents

Publication Publication Date Title
CL2012001596A1 (es) Compuestos derivados de triazolopiridina, pirazolopirimidina, triazolopirimidina o pirazolopiridina, modulador alosterico positivo del receptor mglur5; composicion farmaceutica que los comprende; y su uso en el tratamiento y/o prevencion de la esquizofrenia o de una enfermedad cognitiva.
CL2012002355A1 (es) Compuestos derivados de 1,3,4,8-tetrahidro-2h-pirido[1,2-a]pirazina; composicion farmaceutica que los comprende; kit farmaceutico; y su uso como inhibidores de la integrasa del vih para el tratamiento de una enfermedad infecciosa del vih.
ECSP109934A (es) Compuesto - 946
CR20110599A (es) Composiciones farmacéuticamente activas que comprenden moduladores de estrés oxidativo (osm), nuevas entidades químicas, composiciones y usos
CL2009000161A1 (es) Compuestos derivados de 2,3,4,5-tetrahidro-1h-pirido[4,3-b]indol; composicion farmaceutica que los comprende; uso en el tratamiento de trastornos neurodegenerativos, cognitivos o psicoticos, enfermedad de alzheimer, entre otros; y un kit que contiene a los compuestos.
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
CL2009000483A1 (es) Compuestos derivados de n-(piridin-3-il)-1,3-tiazol-5-amino-4-carboxamida, inhibidores de cinasa pim; composicion farmaceutica; y uso para el tratamiento del cancer.
UY31806A (es) Compuestos de tiazole y oxazole de sulfonamida de benceno
UY30759A1 (es) Compuestos quimicos
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
CL2013000351A1 (es) Compuestos derivados de 2-(arilamino)-3h-imidazo[4,5-b]piridina-6-carboxamida; inhibidores de la prostaglandina e2 sintasa-1 microsomal (mpges-1) composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos para el tratamiento de enfermedades inflamatorias.
CL2008001540A1 (es) Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer.
CO6290656A2 (es) Derivados heterociclicos de urea y metodos de uso de los mismos -211
CL2008002049A1 (es) Compuestos derivados de aminoindol macrociclicos; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
CL2008002430A1 (es) Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc.
CL2012001072A1 (es) Compuestos derivados de feniletinilo, moduladores alostericos positivos del receptor de glutamato (mglur5); procedimiento de preparacion; composicion farmaceutica; y uso para tratar esquizofrenia o enfermedades cognitivas.
ECSP099776A (es) Moduladores de la gamma secretasa
UY33984A (es) Uso de 2,3-dihidroimidazo [1,2-c] quinazolinas sustituidas
UY30308A1 (es) Moduladores de mglur5 v
CL2012002887A1 (es) Combinación farmacéutica que comprende compuestos derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida, compuestos derivados de n-(2-arilamino)arilsulfonamida y opcionalmente otros agentes farmacéuticos adicionales; kit faramacéutico; método de tratamiento; y su uso para el tratamiento o la profilaxis del cáncer.
BR112012022243A8 (pt) Uso de um inibidor de autofagia baseado em tioxantona e de um composto indutor de autofagia para terapia de câncer, composição farmacêutica e kit farmacêutico
CL2009000084A1 (es) Compuestos derivados de sulfonamida sustituida, moduladores de receptores de bradiquinina; composicion farmaceutica que contiene a los compuestos; y uso en el tratamiento del dolor agudo, neuropatico o cronico, entre otros.
GT200600200A (es) Composicion farmaceutica que contienen gestagenos y/o estrogenos y 5-metil-(6s)-tetrahidrofolato
UY32674A (es) Derivados heterociclicos de la urea y sus metodos de empleo
SV2010003752A (es) Derivados de urea heterociclicos para el tratamiento de infecciones bacterianas